Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over
Closed for comments This consultation ended on at Request commenting lead permission
4 Evaluation committee members and NICE project team
Evaluation committee members
The highly specialised technologies evaluation committee is a standing advisory committee of NICE.
Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.
The minutes of each evaluation committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.
Chair
Paul Arundel
Chair, highly specialised technologies evaluation committee
NICE project team
Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser, a project manager and an associate director.
Alan Moore
Technical adviser
Thomas Feist
Project manager
Richard Diaz
Associate director
ISBN: [to be added at publication]
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation